|
1
|
Huang J, Tang H, Cao S, He Y, Feng Y, Wang
K and Zheng Q: Molecular targets and associated potential pathways
of danlu capsules in hyperplasia of mammary glands based on systems
pharmacology. Evid Based Complement Alternat Med. 2017:19305982017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meyer JS: Cell proliferation in normal
human breast ducts, fibroadenomas, and other ductal hyperplasias
measured by nuclear labeling with tritiated thymidine. Effects of
menstrual phase, age, and oral contraceptive hormones. Hum Pathol.
8:67–81. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hartmann LC, Degnim AC, Santen RJ, Dupont
WD and Ghosh K: Atypical hyperplasia of the breast-risk assessment
and management options. N Engl J Med. 372:78–89. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oh H, Eliassen AH, Wang M, Smith-Warner
SA, Beck AH, Schnitt SJ, Collins LC, Connolly JL, Montaser-Kouhsari
L, Polyak K and Tamimi RM: Expression of estrogen receptor,
progesterone receptor, and Ki67 in normal breast tissue in relation
to subsequent risk of breast cancer. NPJ Breast Cancer.
2:160322016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee S, Mohsin SK, Mao S, Hilsenbeck SG,
Medina D and Allred DC: Hormones, receptors, and growth in
hyperplastic enlarged lobular units: Early potential precursors of
breast cancer. Breast Cancer Res. 8:R62006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wood CE, Hester JM, Appt SE, Geisinger KR
and Cline JM: Estrogen effects on epithelial proliferation and
benign proliferative lesions in the postmenopausal primate mammary
gland. Lab Invest. 88:938–948. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wurtman RJ, Axelrod J and Phillips LS:
Melatonin synthesis in the pineal gland: Control by light. Science.
142:1071–1073. 1963. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Majidinia M, Reiter RJ, Shakouri SK and
Yousefi B: The role of melatonin, a multitasking molecule, in
retarding the processes of ageing. Ageing Res Rev. 47:198–213.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mura MC, Luridiana S, Pulinas L, Bizzarri
D, Cosso G and Carcangiu V: Melatonin treatment and male
replacement every week on the reproductive performance in Sarda
sheep breed. Theriogenology. 135:80–84. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arendt J, Bojkowski C, Folkard S, Franey
C, Marks V, Minors D, Waterhouse J, Wever RA, Wildgruber C and
Wright J: Some effects of melatonin and the control of its
secretion in humans. Ciba Found Symp. 117:266–283. 1985.PubMed/NCBI
|
|
11
|
Zhdanova IV, Wurtman RJ, Regan MM, Taylor
JA, Ping SJ and Leclair OU: Melatonin treatment for age-related
insomnia. J Clin Endocrinol Metab. 86:4727–30. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cutando A, López-Valverde A,
Arias-Santiago S, DE Vicente J and DE Diego RG: Role of melatonin
in cancer treatment. Anticancer Res. 32:2747–2753. 2012.PubMed/NCBI
|
|
13
|
Szczepanik M: Melatonin and its influence
on immune system. J Physiol Pharmacol. 58 (Suppl 6):S115–S124.
2007.
|
|
14
|
Amin N, Shafabakhsh R, Reiter RJ and Asemi
Z: Melatonin is an appropriate candidate for breast cancer
treatment: Based on known molecular mechanisms. J Cell Biochem.
120:12208–12215. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang BH and Liu LZ: PI3K/PTEN signaling
in angiogenesis and tumorigenesis. Adv Cancer Res. 102:19–65. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Franke TF, Yang SI, Chan TO, Datta K,
Kazlauskas A, Morrison DK, Kaplan DR and Tsichlis PN: The protein
kinase encoded by the Akt proto-oncogene is a target of the
PDGF-activated phosphatidylinositol 3-kinase. Cell. 81:727–736.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mccubrey J, Steelman LS, Abrams SL, Lee
JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA,
D'Assoro AB, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT
pathways in malignant transformation and drug resistance. Adv
Enzyme Regul. 46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sainsbury R: Benign disorders and diseases
of the Breast. Breast. 1:113. 1992. View Article : Google Scholar
|
|
19
|
Chen CQ and Dan Y: Research of changes of
endocrine hormones in mammary cancer and hyperplasia of mammary
glands. J Modern Oncol. 6:57–59. 2005.(In Chinese with English
abstract).
|
|
20
|
Hartmann LC, Sellers TA, Frost MH, Lingle
WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS,
Hillman DW, et al: Benign breast disease and the risk of breast
cancer. N Engl J Med. 353:229–237. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Knabben L and Mueller MD: Breast cancer
and pregnancy. Horm Mol Biol Clin Investig. 322017.doi:
10.1515/hmbci-2017-0026.
|
|
22
|
Wang L, Zhao D, Di L, Cheng D, Zhou X,
Yang X and Liu Y: The anti-hyperplasia of mammary gland effect of
Thladiantha dubia root ethanol extract in rats reduced by
estrogen and progestogen. J Ethnopharmacol. 134:136–140. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li HT, Liu HH, Yang YX, Wang T, Zhou XL,
Yu Y, Li SN, Zheng Y, Zhang P, Wang RL, et al: Therapeutic effects
of a traditional Chinese medicine formula plus tamoxifen vs.
Tamoxifen for the treatment of mammary gland hyperplasia: A
meta-analysis of randomized trials. Front Pharmacol. 9:452018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Goldstein SR, Suresh S, Ciaccia AV and
Plouffe L Jr: Apharmacological review of selective oestrogen
receptor modulators. Hum Reprod Update. 6:212–224. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Henry NL: Endocrine therapy toxicity:
Management options. Am Soc Clin Oncol Educ Book. e25–e30. 2014.doi:
10.14694/EdBook_AM.2014.34.e25. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Muskhelishvili L, Latendresse JR, Kodell
RL and Henderson EB: Evaluation of cell proliferation in rat
tissues with BrdU, PCNA, Ki-67(MIB-5) immunohistochemistry and in
situ hybridization for histone mRNA. J Histochem Cytochem.
51:1681–1688. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Duan WR, Garner DS, Williams SD,
Funckes-Shippy CL, Spath IS and Blomme EA: Comparison of
immunohistochemistry for activated caspase-3 and cleaved
cytokeratin 18 with the TUNEL method for quantification of
apoptosis in histological sections of PC-3 subcutaneous xenografts.
J Pathol. 199:221–228. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang J, Xiao X, Zhang Y, Shi D, Chen W, Fu
L, Liu L, Xie F, Kang T, Huang W and Deng W: Simultaneous
modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin
to inhibit proliferation and induce apoptosis in breast cancer
cells. J Pineal Res. 53:77–90. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oda K, Stokoe D, Taketani Y and McCormick
F: High frequency of coexistent mutations of PIK3CA and PTEN genes
in endometrial carcinoma. Cancer Res. 65:10669–10673. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ming M and He YY: PTEN: New insights into
its regulation and function in skin cancer. J Invest Dermatol.
129:2109–2112. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Janaki RM and Vaishnave S: BMI1 and PTEN
are key determinants of breast cancer therapy: A plausible
therapeutic target in breast cancer. Gene. 678:302–311. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kwabi-Addo B, Giri D, Schmidt K,
Podsypanina K, Parsons R, Greenberg N and Ittmann M:
Haploinsufficiency of the Pten tumor suppressor gene promotes
prostate cancer progression. Proc Natl Acad Sci USA.
98:11563–11568. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Giri D and Ittmann M: Inactivation of the
PTEN tumor suppressor gene is associated with increased
angiogenesis in clinically localized prostate carcinoma. Hum
Pathol. 30:419–424. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bonneau D and Longy M: Mutations of the
human PTEN gene. Hum Mutat. 16:109–122. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guillard S, Clarke PA and Workman P:
Investigating the function of class I phosphatidylinositol 3-kinase
isoforms in glioma cell lines by siRNA-mediated depletion. Cancer
Res. 66:998. 2006.
|
|
36
|
Wei Y, Stec B, Redfield AG, Weerapana E
and Roberts MF: Phospholipid-binding sites of phosphatase and
tensin homolog (PTEN): Exploring the mechanism of
phosphatidylinositol 4,5-bisphosphate activation. J Biol Chem.
290:1592–606. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Goschzik T, Gessi M, Denkhaus D and
Pietsch T: PTEN mutations and activation of the PI3K/Akt/mTOR
signaling pathway in papillary tumors of the pineal region. J
Neuropathol Exp Neurol. 73:747–751. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Leslie NR, Kriplani N, Hermida MA,
Alvarez-Garcia V and Wise HM: The PTEN protein: Cellular
localization and post-translational regulation. Biochem Soc Trans.
44:273–278. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Datta SR, Brunet A and Greenberg ME:
Cellular survival: A play in three Akts. Genes Dev. 13:2905–2927.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dennis PA: The PI3K/Akt/mTOR signaling
pathway. Ann Oncol. 192011.PubMed/NCBI
|
|
41
|
Lu XX, Cao LY, Chen X, Xiao J and Chen Q:
PTEN inhibits cell proliferation, promotes cell apoptosis, and
induces cell cycle arrest via downregulating the PI3K/AKT/hTERT
pathway in lung adenocarcinoma A549 cells. Biomed Res Int.
2016:24768422016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
He L, Fan C, Gillis A, Feng X, Sanatani M,
Hotte S, Kapoor A and Tang D: Co-existence of high levels of the
PTEN protein with enhanced Akt activation in renal cell carcinoma.
Biochim Biophys Acta. 1772:1134–1142. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
